The Sabra Health Care REIT’s (SBRA) Neutral Rating Reaffirmed at Mizuho

The Sabra Health Care REIT’s (SBRA) Neutral Rating Reaffirmed at Mizuho

Mizuho reiterated their neutral rating on shares of Sabra Health Care REIT Inc (NASDAQ:SBRA) in a report issued on Monday. The brokerage currently has a $23.00 price target on the stock.

A number of other equities analysts have also weighed in on SBRA. TheStreet upgraded Sabra Health Care REIT from a hold rating to a buy rating in a research note on Tuesday, August 2nd. Zacks Investment Research upgraded Sabra Health Care REIT from a hold rating to a buy rating and set a $23.00 price target for the company in a research note on Tuesday, July 5th. Bank of America Corp. lowered Sabra Health Care REIT from a neutral rating to an underperform rating in a research note on Monday, July 25th. Cantor Fitzgerald began coverage on Sabra Health Care REIT in a research note on Thursday, June 23rd. They issued a buy rating and a $28.00 price target for the company. Finally, JMP Securities restated a hold rating on shares of Sabra Health Care REIT in a research note on Friday, September 9th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of Hold and a consensus price target of $23.75.

Sabra Health Care REIT (NASDAQ:SBRA) opened at 23.55 on Monday. Sabra Health Care REIT has a 52 week low of $14.92 and a 52 week high of $26.40. The company has a market capitalization of $1.54 billion, a price-to-earnings ratio of 28.14 and a beta of 1.05. The company’s 50-day moving average price is $24.47 and its 200-day moving average price is $22.42.

Sabra Health Care REIT (NASDAQ:SBRA) last released its quarterly earnings data on Monday, August 1st. The company reported $0.61 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.58 by $0.03. The business earned $74.20 million during the quarter, compared to analyst estimates of $56.04 million. Sabra Health Care REIT had a return on equity of 6.27% and a net margin of 24.63%. The company’s revenue was up 31.1% on a year-over-year basis. During the same quarter last year, the business posted $0.53 EPS. Equities analysts forecast that Sabra Health Care REIT will post $2.28 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Nuveen Asset Management LLC raised its stake in shares of Sabra Health Care REIT by 1,393.6% in the second quarter. Nuveen Asset Management LLC now owns 1,021,636 shares of the company’s stock worth $21,081,000 after buying an additional 953,235 shares during the period. Vanguard Group Inc. raised its stake in shares of Sabra Health Care REIT by 3.0% in the second quarter. Vanguard Group Inc. now owns 10,251,855 shares of the company’s stock worth $211,547,000 after buying an additional 302,868 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Sabra Health Care REIT by 74.2% in the second quarter. JPMorgan Chase & Co. now owns 664,139 shares of the company’s stock worth $13,705,000 after buying an additional 282,887 shares during the period. Systematic Financial Management LP purchased a new stake in shares of Sabra Health Care REIT during the second quarter worth about $4,343,000. Finally, Opus Capital Group LLC purchased a new stake in shares of Sabra Health Care REIT during the second quarter worth about $3,726,000. 92.14% of the stock is owned by institutional investors and hedge funds.

About Sabra Health Care REIT

Related posts

Leave a Comment